Status:
COMPLETED
Protein and RNA Expression Patterns in Predicting Response to Treatment in Patients With Lung Cancer
Lead Sponsor:
Vanderbilt-Ingram Cancer Center
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Lung Cancer
Eligibility:
All Genders
Up to 120 years
Brief Summary
RATIONALE: Studying samples of tumor tissue and blood in the laboratory from patients with cancer may help doctors learn more about changes that occur in genetic material (DNA and RNA) and may also id...
Detailed Description
OBJECTIVES: * To determine protein and/or RNA expression patterns capable of predicting tumor response to therapy in tumor tissue samples from patients with lung cancer or suspected of having lung ca...
Eligibility Criteria
Inclusion
- Inclusion criteria
- Diagnosis of suspected lung cancer or lung cancer
- Exclusion criteria
- Inability to undergo therapy
Exclusion
Key Trial Info
Start Date :
December 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2017
Estimated Enrollment :
204 Patients enrolled
Trial Details
Trial ID
NCT00897650
Start Date
December 1 2005
End Date
July 1 2017
Last Update
July 19 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States, 37232-6838